BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has signed an agreement with Comed Medical Specialties (Comed) for the sales and distribution of the MicroThermX Microwave Ablation (MicroThermX) line of products.

Comed Medical Specialties is the number one specialty medical distributor in the Western United States. Comed has a thirty-year history of selling innovative medical devices to the interventional radiology market. Comed has well-established, key relationships with department heads at interventional radiology institutions throughout the West. Comed has 10 sales personnel specializing in selling innovative surgical and interventional radiology products.

Based in Salt Lake City, Utah, Comed has the rights to market the MicroThermX line of products in Arizona, California, Colorado, El Paso, Texas, Nevada, New Mexico, and Utah. Comed’s sales team will work hand-in-hand with BSD sales management and BSD’s direct sales representatives and clinical specialist in the West to penetrate one of the largest target markets for MicroThermX products in the United States.

“We are pleased to partner with a distributor of Comed’s caliber in interventional radiology products, as this is another essential step in presenting the advantages of the MicroThermX to opinion leaders throughout the West,” said Brian Ferrand, BSD Vice President of Domestic Sales. “Comed has long-established relationships with key interventional radiologists and capital equipment purchasers, which will increase sales of our products in the Western United States.”

“The chance to distribute BSD’s MicrothermX product line is exceptionally attractive to Comed,” said Mike Mahoney, Principal with Comed. “Microwave ablation technology is in a rapidly growing market sector for treating cancer and Comed sees a tremendous opportunity to offer MicroThermX to its extensive base of established customers.”

About the MicroThermX Microwave Ablation System

The MicroThermX Microwave Ablation System is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX product line includes an innovative, high-end disposable that is used in each ablation treatment, and provides ongoing revenue streams for BSD. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX system in Europe. CE marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s MicroThermX microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at

This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.

Copyright Business Wire 2010